Cost containment analysis and access to treatment associated with adopting hypofractionated radiation therapy from the Brazilian perspective

Prince Taylor, Marcus Simões Castilho, Gustavo Nader Marta, Prince Taylor, Marcus Simões Castilho, Gustavo Nader Marta

Abstract

Background: Estimates show that breast cancer, the leading cause of cancer death in females worldwide, will continue to increase in incidence, highlighting the need for increased treatment capacity. While postoperative radiation therapy (RT) is commonly used to reduce recurrence and mortality, research has shown that moderately hypofractionated radiation therapy (HFRT) and 5-fraction HFRT are equally safe and effective and can reduce treatment costs. This study aimed to compare the cost of conventional RT (50Gy/25), moderately HFRT (40.05Gy/15), and 5-fraction HFRT (26Gy/5) for breast cancer patients in Brazil.

Methods: The cost of each RT regimen was calculated using the International Atomic Energy Agency's Radiotherapy Cost Estimator Tool. The potential annual savings were then estimated by applying the cost of each regime to the 2020 Brazilian cancer incidence rates.

Findings: The average costs per patient for 25 fractions, 15 fractions, and 5 fractions are $2,699.20, $1,711.98, and $929.81, respectively. The annual cost savings associated with treating 70% of patients with 15 fraction HFRT and 30% of patients with 5 fraction HFRT as compared to treating all patients with 25 fraction RT is $72,929,315.40. The estimated annual productivity of 1 LINAC machine for 25 fractions, 15 fractions, and 5 fractions is 338, 647, and 1,310 patients, respectively.

Interpretation: The cost analysis revealed decreased patients' costs and potential for increased EBRT access associated with HFRT in the Brazilian perspective.

Funding: None.

Keywords: Brazil; Breast cancer; Costs; Hypofractionated; Radiation therapy.

Conflict of interest statement

The authors have declared no conflicts of interest.

© 2022 The Author(s).

Figures

Figure 1
Figure 1
Estimated average patient costs associated with CFRT (25 fractions), moderately HFRT (15 fractions), and ultra HFRT (5 fractions).
Figure 2
Figure 2
Estimated Annual EBRT Productivity of 1 LINAC machine per RT regimen, in terms of number of EBRT courses delivered (1 EBRT course = 1 patient).

References

    1. Ministério da Saúde . Incidência de Câncer no Brasil; Rio de Janeiro: 2020. Instituto Nacional do Câncer. Estimativa 2020.
    1. Mendez LC, Moraes FY, Fernandes G dos S, Weltman E. Cancer deaths due to lack of universal access to radiotherapy in the Brazilian Public Health System. Clin Oncol. 2018;30:e29–e36. doi: 10.1016/j.clon.2017.09.003.
    1. Stebbing J, Delaney G, Thompson A. Breast cancer (non-metastatic) BMJ Clin Evid. 2007;2007
    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288–300. doi: 10.1001/jama.2018.19323.
    1. Marta GN, Coles C, Kaidar-Person O, et al. The use of moderately hypofractionated post-operative radiation therapy for breast cancer in clinical practice: a critical review. Crit Rev Oncol Hematol. 2020;156 doi: 10.1016/j.critrevonc.2020.103090.
    1. Abe O, Abe R, Enomoto K, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet North Am Ed. 2005;366:2087–2106. doi: 10.1016/S0140-6736(05)67887-7.
    1. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. J Natl Cancer Inst. 1994;86:717–722. doi: 10.1093/jnci/86.9.717.
    1. Liljegren G, Holmberg L, Bergh J, et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17:2326–2333. doi: 10.1200/jco.1999.17.8.2326.
    1. Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst. 1996;88:1659–1664. doi: 10.1093/jnci/88.22.1659.
    1. Malmström P, Holmberg L, Anderson H, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003;39:1690–1697. doi: 10.1016/S0959-8049(03)00324-1.
    1. Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–520. doi: 10.1056/nejmoa0906260.
    1. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467–471. doi: 10.1016/S1470-2045(06)70699-4.
    1. Bentzen S, Agrawal R, Aird E, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–341. doi: 10.1016/S1470-2045(08)70077-9.
    1. Agrawal RK, Aird EGA, Barrett JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet North Am Ed. 2008;371:1098–1107. doi: 10.1016/S0140-6736(08)60348-7.
    1. Shaitelman SF, Lei X, Thompson A, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial. J Clin Oncol. 2018;36:3495. doi: 10.1200/JCO.18.00317.
    1. Wang S, Fang H, Hu C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China. J Clin Oncol. 2020;38:3604–3614. doi: 10.1200/JCO.20.01024.
    1. Chua BH, Link E, Kunkler I, et al. Abstract GS2-04: a randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01) Cancer Res. 2021;81 doi: 10.1158/1538-7445.SABCS20-GS2-04.
    1. Offersen B v., Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III Trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–3625. doi: 10.1200/JCO.20.01363.
    1. Wang S, Fang H, Song Y, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20:352–360. doi: 10.1016/S1470-2045(18)30813-1.
    1. Brunt AM, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet North Am Ed. 2020;395:1613–1626. doi: 10.1016/S0140-6736(20)30932-6.
    1. Irabor OC, Swanson W, Shaukat F, et al. Can the adoption of hypofractionation guidelines expand global radiotherapy access? An analysis for breast and prostate radiotherapy. JCO Glob Oncol. 2020:667–678. doi: 10.1200/JGO.19.00261.
    1. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for breast carcinoma. Cancer. 2003;98:1977–1986. doi: 10.1002/CNCR.11740.
    1. International Atomic Energy Agency. Staffing and cost calculation 2008. . Accessed 14 July 2021.
    1. Zubizarreta E, Fidarova E, Healy B, Rosenblatt E. Need for radiotherapy in low and middle income countries – the silent crisis continues. Clin Oncol (R Coll Radiol) 2015;27:107–114. doi: 10.1016/J.CLON.2014.10.006.
    1. Dziemianowicz M, Burmeister J, Dominello M. Basic Original Report Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. Pract Radiat Oncol. 2021;11(4):245–251. doi: 10.1016/j.prro.2021.01.003.
    1. Marta GN, Ramiah D, Kaidar-Person O, et al. The financial impact on reimbursement of moderately hypofractionated postoperative radiation therapy for breast cancer: an international consortium report. Clin Oncol. 2021;33:322–330. doi: 10.1016/j.clon.2020.12.008.
    1. Yaremko HL, Locke GE, Chow R, Lock M, Dinniwell R, Yaremko BP. Cost minimization analysis of hypofractionated radiotherapy. Curr Oncol. 2021;28(1):716–725. doi: 10.3390/curroncol28010070.
    1. Marta GN, Riera R, Pacheco RL, et al. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials. Breast. 2022;62:84–92. doi: 10.1016/j.breast.2022.01.018.
    1. Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1 January):e21–e31. doi: 10.1016/S1470-2045(21)00539-8.
    1. Najas GF, Stuart SR, Marta GN, et al. Hypofractionated radiotherapy in breast cancer: a 10-year single institution experience. Rep Pract Oncol Radiother. 2021 Dec 30;26(6):920–927. doi: 10.5603/RPOR.a2021.0109.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe